3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Thoracic
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Azacitidine
68
nilotinib
50
Imatinib Mesylate
50
ruxolitinib
42
Dasatinib
25
venetoclax
22
Decitabine
20
bosutinib
18
asciminib
17
Cytarabine
15
ponatinib
10
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
9
fludarabine
8
Hydroxyurea
8
navitoclax
6
ON 01910
6
sabatolimab
5
pevonedistat
5
mocetinostat
5
luspatercept
5
itacitinib
5
imetelstat
5
givinostat hydrochloride
5
givinostat
5
fludarabine phosphate
5
avapritinib
5
Mycophenolic Acid
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Tyrosine Kinase Inhibitors
×
Myeloid
×
Clear all
NCT05476562
2022-11-08
Study Conducted Among Patients With CML
Novartis
Completed
3,234 enrolled